For decades, the discourse surrounding HIV prevention has been haunted by a persistent, unscientific fear: the belief that providing the tools to prevent infection would encourage recklessness. As Kenya begins its nationwide rollout of game-changing, long-acting injectable pre-exposure prophylaxis (PrEP), that narrative is being dismantled not by rhetoric, but by rigorous clinical data. The medical reality is clear—effective prevention is a lifeline, not a license for irresponsibility.

This debate gained renewed urgency this month as the Ministry of Health, through the National AIDS and STIs Control Programme (NASCOP), initiated the rollout of Lenacapavir. This twice-yearly injectable drug marks a pivotal shift in the nation’s HIV strategy, yet it arrived amidst lingering societal resistance rooted in the "risk compensation" hypothesis—the assumption that individuals on PrEP will abandon other precautions, like condoms, thereby increasing their exposure to other sexually transmitted infections. Recent evidence from high-burden regions like Kisumu, however, refutes this, demonstrating that access to preventive medicine empowers, rather than endangers, vulnerable populations.

The Anatomy of the Myth

The fear of risk compensation has long served as a barrier to scaling up HIV prevention programs. Critics often argue that biomedical interventions might create a false sense of security. However, systematic reviews and local demonstration projects have consistently shown that participants do not engage in riskier sexual behavior upon accessing PrEP. In fact, many individuals who seek PrEP are often those who are already acutely aware of their vulnerability and are taking proactive steps to manage their sexual health.

Data from recent studies tracking cohorts of women in Western Kenya highlights this shift in perspective. Participants on PrEP did not experience higher rates of sexually transmitted infections compared to those who were not on the medication. Instead, the process of accessing care—which includes regular counseling and health education—often leads to better overall sexual health outcomes. When individuals are engaged with the healthcare system, they are more likely to receive testing, education, and support, effectively debunking the myth that pharmaceutical intervention leads to moral or behavioral decay.

The Numbers Behind the Shield

Kenya continues to make significant strides in its HIV response, yet the epidemic remains a potent threat to public health. According to data from the National Syndemic Diseases Control Council (NSDCC), there are approximately 1.4 million Kenyans living with HIV, representing a prevalence of roughly 3.7 percent. While new HIV infections have dropped significantly—from over 100,000 in 2013 to approximately 15,000 in 2024—prevention remains the most critical pillar in the effort to reach the national goal of ending AIDS as a public health threat by 2030.

• Impact of PrEP Rollout: Kenya saw a 4,000 percent increase in PrEP users between 2016 and 2023, moving from fewer than 10,000 to over 438,000 users.
• The Lenacapavir Rollout: Phase one of the rollout, which began in March 2026, targets 15 high-burden counties, including Nairobi, Kisumu, Homa Bay, Migori, and Mombasa.
• Clinical Efficacy: Clinical studies have indicated that Lenacapavir can be up to 96 percent effective in preventing HIV infection, offering a long-acting alternative to daily pill regimens.
• Financial Context: While initial starter doses were provided through international partnerships, the government is tasked with sustaining the program, which faces a challenging funding landscape following shifts in global health aid, including the restructuring of U.S.-backed HIV support.

Overcoming Structural Barriers

The transition from daily oral PrEP—which carries the burden of daily adherence and pill fatigue—to twice-yearly injections is designed specifically to address the realities of modern life. For many, particularly young women and key populations facing stigma, the daily pill acts as a visible marker of their HIV status or sexual activity, creating a hurdle to consistent use. The injectable form offers a level of discretion that can significantly improve retention rates.

Dr. Jonah Onentiah, the PrEP Programme Technical Lead at NASCOP, has consistently emphasized that medical tools work best when they are integrated into a comprehensive prevention package. This package is not merely the drug itself, but the entire support system surrounding the patient—counseling, testing, and behavioral education. Policymakers and community leaders must recognize that HIV prevention is a human rights issue. By focusing on the efficacy of the drug rather than the moral judgment of the patient, the health sector can dismantle the barriers that keep individuals away from clinics.

A Global Standard for Prevention

Kenya is not acting in isolation. As a regional leader, the country’s aggressive adoption of Lenacapavir places it among the first nations in East Africa to deploy this technology. Global evidence from the U.S., South Africa, and parts of Europe reinforces the Kenyan experience: when barriers to access are lowered, and when prevention is treated as a healthcare priority rather than a moral issue, infection rates decline. The stigma that once surrounded antiretroviral therapy (ART) in the early 2000s is now being replicated in the discourse around PrEP. History shows that public health initiatives succeed when they are grounded in science and human dignity, and fail when they are dictated by prejudice.

As Kenya moves forward with the next phases of the rollout, the focus must remain on sustainability and education. The tragic reality of the epidemic is not that preventive tools encourage risk, but that the failure to provide those tools ensures the virus continues to spread among those who are most vulnerable. The most dangerous behavior is not the use of prevention, but the silence and stigma that prevent it from reaching those who need it most.